Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MBRX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Liposomal Annamycin | Leukemia, Myeloid, Acute | Phase 1/2 · NCT05319587 | Completed |
| MOL4239 | Psoriasis | Phase 2 · NCT01826201 | Completed |
| STAT3 Inhibitor WP1066 | Glioblastoma, IDH-Wildtype | Phase 2 · NCT05879250 | Recruiting |
| WP1122 | Healthy Volunteer | Phase 1 · NCT05195723 | Completed |
| WP1220 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Phase 1 · NCT04702503 | Completed |
Also used in these trials (approved or third-party drugs, not MBRX's own candidates): Cytarabine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MBRX holds $7.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.4M/quarter from operations, an estimated runway of 3.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
These factors raise substantial doubt regarding the Company's ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MBRX files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MBRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →